STATISTICAL ANALYSIS PLAN (SAP)

**Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Study**

**Houston Data Coordinating Center**

**PI:** Jose-Miguel Yamal, PhD  
**Co-Investigator:** Suja S. Rajan, PhD  
**UTHHealth, School of Public Health**  
**Houston, TX 77030**

June 2017

updated March 2018 (sensitivity analysis of utility weights, adjusted analysis for TM subgroup analysis)

updated January 2019 (include a pre-specified subgroup of EMS arrival <1 hr vs >1 hr from last seen normal)

updated February 2020 (include clarification of the modified ITT analysis and sensitivity analyses)
Table of Contents

1. STUDY OVERVIEW ........................................................................................................... 4
   1.1. Objective and Study Design ..................................................................................... 4

2. DEFINITION OF TARGET POPULATION AND STUDY SAMPLES ........................................... 4
   2.1. Target Population .................................................................................................... 4
   2.2. Study Outcomes ..................................................................................................... 5
       2.2.1. Primary Outcomes ........................................................................................ 5
       2.2.2. Secondary Outcomes ................................................................................... 5
       2.2.3. Safety Outcomes .......................................................................................... 6

3. GENERAL STATISTICAL CONSIDERATIONS ..................................................................... 7
   3.1. Randomization (The process is described in detail in the protocol) ..................... 7
   3.2. Blinding .................................................................................................................. 8
   3.3. Multiplicity ............................................................................................................. 8

4. SAMPLE SIZE DETERMINATION ....................................................................................... 8
   4.1. Sample Size for the Phase III trial .......................................................................... 8

5. ANALYSIS PLAN ............................................................................................................... 10
   5.1. Phase III Trial Analysis .......................................................................................... 10
       5.1.1. Treatment Group Comparability at Baseline ................................................ 10
       5.1.2. Primary Clinical Analysis .............................................................................. 11
       5.1.3. Sensitivity Analysis of Primary Outcome ...................................................... 11
       5.1.4. Analyses of Ancillary Clinical Outcomes ...................................................... 12
       5.1.5. Subgroup Analysis ......................................................................................... 13

6. MONITORING FOR EFFECTIVENESS AND SAFETY ............................................................ 13
   6.1. Overview ............................................................................................................... 13
   6.2. Interim Analyses for Effectiveness ...................................................................... 13
   6.3. Interim Analyses for Futility ............................................................................... 13
   6.4. Safety Analyses ................................................................................................... 14
   6.5. Process Analysis ................................................................................................... 14

7. REPORTING PROCEDURES ............................................................................................. 14
   7.1. CONSORT Diagram ............................................................................................. 14
   7.2. Primary Reporting for the BEST-MSU Study ....................................................... 14
   7.3. SMC Reports ........................................................................................................ 14
   7.4. Publications .......................................................................................................... 14
8. REFERENCES
1. **STUDY OVERVIEW**

1.1. **Objective and Study Design**

The primary goal of this project is to carry out a trial comparing pre-hospital diagnosis and treatment of patients with stroke symptoms using a Mobile Stroke Unit (MSU) with subsequent transfer to a Comprehensive Stroke Center (CSC) Emergency Department (ED) for further management, to standard pre-hospital triage and transport by Emergency Medical Services (EMS) to a CSC ED for evaluation and treatment (Standard Management-SM).

There are many ways that use of a MSU might prove valuable in stroke patients, but we will focus on acute ischemic stroke (AIS) and treatment with IV tissue plasminogen activator (tPA) within 4.5 hours of symptom onset since that is the most evidence based effective emergency treatment for the most prevalent stroke diagnosis. We hypothesize that the MSU pathway will produce an overall shift towards earlier evaluation and treatment, particularly into the first hour after symptom onset, leading to substantially better outcome. To make MSU deployment more practical, we will confirm that a Vascular Neurologist (VN) on board the MSU can be replaced by a remote VN connected to the MSU by telemedicine (TM) thereby reducing manpower requirements and costs.

The successful completion of this project will provide data on important outcomes associated with the use of MSU vs SM in the United States (U.S.) that will determine the value of integrating MSUs into the pre-hospital environment that would be more generalizable throughout the country. Therefore, the proposed study is the necessary step in a process that may dramatically modify the way that acute stroke patients are managed.

This is a prospective multicenter cohort study with randomized deployment weeks and blinded assessment of both trial entry and clinical outcomes.

2. **DEFINITION OF TARGET POPULATION AND STUDY SAMPLES**

2.1. **Target Population**

No. of Clinical Sites: 6
No. of subjects:
   - To be assessed for eligibility (n = 4900)
   - To be enrolled (n = 1845)
   - To be analyzed (“tPA eligible”) (n = 1038)

*Main criteria for inclusion:*

1. Criteria for MSU team to **enroll** a patient into the study (to be determined pre-hospital on both MSU and SM weeks)
   a. Last seen normal possibly within 4 hr 30 min
   b. History and physical/neurological examination consistent with acute stroke
c. No definite tPA exclusions per guidelines, prior to CT scan or baseline labs

d. Informed consent obtained from patient (if competent) or legal representative. Prehospital management and treatment, including IV tPA, will not be delayed for consent; however, consent in both MSU and SM patients must eventually be obtained for data to be retained for analysis.

2. Criteria for **tPA-eligibility** (to be determined pre-hospital on MSU weeks, and after ED assessment on SM weeks, and confirmed by blinded adjudication)

   a. Meeting tPA inclusion and exclusion criteria per guidelines after CT scan, baseline labs, and clinical re-evaluation

---

### 2.2. Study Outcomes

#### 2.2.1. Primary Outcomes

- The utility-weighted modified Rankin Scale (mRS) at 90 days, comparing patients found eligible for tPA (based on a blinded review of the patient’s chart, regardless of whether they were treated or not) on MSU weeks compared to patients on SM weeks.

#### 2.2.2. Secondary Outcomes

- The agreement between the VN on board the MSU with a VN remotely assessing a suspected stroke patient for treatment with tPA via TM in the MSU, and the rate of technical failures in conducting the TM consultation. N.B. Patients will include all enrolled patients on MSU weeks considered for tPA treatment.

- Of enrolled patients treated with tPA within 60 minutes of LSN onset according to published guidelines on either MSU or SM weeks, compared to similar patients treated 61-270 minutes after onset, adjusting for any imbalances in stroke severity (baseline NIHSS) between the groups at the time of treatment. N.B. Patients will include only those patients actually treated with tPA based on the final determination of the time LSN, and will include only patients meeting all inclusion and exclusion criteria.

  - Change in utility-weighted mRS from baseline to 90 days,
  - ordinal (shift) analysis of mRS at 90 days, and
  - proportion of patients achieving 90-day mRS 0,1 vs 2-6

- Comparing patients found eligible for tPA (based on a blinded review of the patient’s chart, regardless of whether they were treated or not) on MSU weeks compared to
patients on SM weeks.
  o ordinal (shift) analysis of mRS at 90 days, and
  o proportion of patients achieving 90-day mRS 0,1 vs 2-6

• The time from LSN to tPA treatment on all patients treated within 4.5 hours of LSN on MSU weeks compared to similarly eligible patients on SM weeks. N.B. Patients will include all enrolled patients actually treated with tPA (or on SM weeks, eligible for tPA treatment) meeting all inclusion and exclusion criteria, and based on the final determination of time of LSN. One analysis will compare the median times. A second analysis will also capture the patients who were eligible but did not receive tPA because it was too late, categorizing time into the following groups (e.g., 0-60min, 61-90min, 91min-180min, 181-270min, eligible but no tmt because>270).

• Of the enrolled patients that were eligible for treatment with tPA (according to published guidelines) on MSU weeks compared to SM weeks, the percent that were treated within 4.5 hours and within 60 minutes of LSN.

• The time from LSN, from alarm time, and from ED arrival to start of endovascular procedure (intra-arterial thrombectomy-IAT) in patients who meet pre-specified criteria for IAT on MSU weeks compared to SM weeks. N.B. All patients receiving IAT will be included in this outcome.

• The proportion of all tPA-eligible patient having IAT on MSU weeks compared to SM weeks

• The median/mean time from LSN to tPA therapy decision on all patients considered for treatment within 4.5 hours of LSN on MSU weeks compared to SM weeks. N.B. Patients will include all enrolled patients meeting inclusion criteria whether or not treated with tPA.

• Time between 911 call and onset of etiology-specific BP management on MSU weeks compared to SM weeks. N.B. Patients will include all enrolled patients.

2.2.3. Safety Outcomes

• The incidence of symptomatic intracranial hemorrhage (sICH) in enrolled tPA treated patients on MSU weeks compared to SM weeks (Symptomatic intracranial hemorrhage defined as any intracranial blood accumulation associated with a clinical deterioration of ≥4 points of the NIHSS for which the hemorrhage has been identified as the dominating cause of the neurologic deterioration) N.B. Patients will include all patients treated with tPA, whether or not they meet all inclusion and exclusion criteria.

• Mortality. N.B. All enrolled patients signing informed consent will be included in this endpoint and followed until 1 year.
The incidence of stroke mimics and transient ischemic attacks (TIAs) in tPA-treated patients, and also in tPA-eligible patients, on MSU weeks compared to SM weeks. N.B. SM patients deemed eligible for tPA on their pre-hospital assessment who then completely recover by the time of arrival in the ED will equal the excess incidence of TIAs treated on the MSU pathway.

3. GENERAL STATISTICAL CONSIDERATIONS

3.1. Randomization and Analytic Cohorts (The process is described in detail in the protocol)

Weeks when the MSU is available or not are randomly selected. Stroke events are orthogonal to whether the MSU was being deployed or not that week and thus participants will be randomly entered into either the MSU or SM groups depending on when their stroke occurs.

The primary analytic cohort is based on a modified intention-to-treat (ITT) analysis where the subject will be assigned to the group that they were enrolled in (e.g. if a patient was enrolled using SM, they would be assigned to the SM group) and adjudicated (by the blinded adjudicator) to be tPA eligible. The usual ITT includes every subject who is randomized according to randomized treatment assignment. In this study, all patients within each group who are adjudicated as tPA eligible by an adjudicator blinded to group assignment are included. The randomized assignment is not conducted for each patient, rather we generally alternated weeks to be either MSU or SM weeks, which is independent of when a subject randomly has a stroke and calls 911. Therefore, this may be considered a cluster-randomized trial where the cluster is the days when the MSU is available and the other cluster is when MSU is not available. There is not anything clinically important to set the cluster of when the MSU was available or not as a week (e.g., an alternative design could set one week as having MWF as MSU days and TTH as SM days and the next week as the opposite), but this made it convenient to set work schedules and to have a similar amount of time dedicated to recruitment of MSU and SM subjects and there is not a scientific nor statistical rationale suggesting that the clusters would be related to the patient’s outcomes and intervention effect. Patients are, in a sense, “randomly” allocated into the clusters based entirely on when they happen to have their stroke in relation to the prospectively determined cluster allotment of whether the MSU is available or not. Furthermore, in order to optimize the utilization of the MSU, some cities have 2 sites enrolling patients at the same time, with one site running the MSU and other enrolling SM patients and then they switch the next week.

There are a few cases when the MSU was not available during an “MSU week” (e.g. the unit is out of service on another call, had to be serviced for an oil change, staff were sick and therefore unable to come in) and stroke patients that were treated using standard management were enrolled into the study by the study team into the SM arm. These few subjects will be included in the primary analysis in the SM arm, but moved to the MSU arm in a sensitivity analysis (see section 5.1.3). The decision to include them in the primary analysis is based on a November, 2019 comparison of the SM subjects who were enrolled during an “MSU week” compared to the SM subjects enrolled during an “SM week”. Baseline characteristics (age, sex, ethnicity, race, pre-stroke mRS, baseline NIHSS, tPA treatment, time from LSN to tPA bolus, endovascular treatment, and DTGP) were similar between the groups, confirming our belief that there should not be any added bias for including
them in the primary analysis. The benefit of including them is to improve the MSU:SM ratio and to increase the chance of recruiting subjects according to the projected timeline. However, this analysis will be repeated at the end of the study to confirm that no significant differences exist between these two SM populations before including them in the MSU arm.

3.2. Blinding

Blinded assessment of both trial entry, tPA-eligibility, and study outcomes. All patients are screened for trial enrollment during their pre-hospital evaluation and management by the same investigators on both MSU and SM weeks to ensure that comparisons are made between similar patients, using similar criteria, at a similar stage of illness. For enrolled patients, criteria for study enrollment and tPA treatment are subsequently reviewed by a vascular neurologist (VN) blinded to MSU vs SM assignment and not otherwise involved in study management or analysis. The blinded VN determines from a dedicated “adjudication form”, omitting any time data or other information that would produce unblinding, if the patient meets criteria for study enrollment and for tPA treatment. For comparing outcomes between MSU and SM, we will only include tPA-eligible patients on both MSU and SM weeks, whether or not actually treated, based on this blinded review. Investigators obtaining all outcomes are blinded to treatment allocation.

3.3. Multiplicity

No adjustments for multiple comparisons will be made. However, the secondary analyses will be interpreted with caution.

4. SAMPLE SIZE DETERMINATION

4.1. Sample Size for the Phase III trial

The power of this trial was based on the difference in primary outcome, 90 d uw-mRS. Based on preliminary data, we expected 1.8 times as many MSU as SM patients because when we began the study, on SM weeks some patients were occasionally taken by EMS to non-participating stroke centers where they could not be enrolled into the study. On MSU weeks, these patients would be transported in the MSU only to participating hospitals and therefore enrolled. Subsequently, we have incorporated these non-participating hospitals into the study, thereby mitigating this gap and the groups are now balanced. With a sample size of 693 total tPA-eligible patients (446 MSU and 247 SM patients, assuming 10% lost to follow-up [LTF]), the study will have 80% power with a 0.05 Type I error to detect a difference between groups of 0.09 in the mean uw-mRS using a two-sample t-test. This difference is plausible and important. In a re-analysis of 11 acute stroke studies, the difference in mean 90d uw-mRS between groups ranged from 0.024-0.25, with most positive trials in the range of 0.1. In the NINDS tPA trial, 90d uw-mRS difference was 0.09 between tPA and placebo.

In March, 2018, Dr. Grotta, blinded to study data, requested, and PCORI approved, an increased sample size to 1095 patients from the 693 initially requested, and to allow three additional sites to be added. This request was based on our reassessment of anticipated
difference in 90 day uw-mRS based on a.) results of the Berlin non-randomized study which showed a 0.07 difference between MSU and control patients, b.) results of the DAWN trial which was the first completed study to use the uw-mRS, and c.) reanalysis of a substantial number of completed stroke trials where conventional mRS outcomes were translated to uw-mRS (see figure below). In that analysis, Broderick et al found that the smallest clinically meaningful difference was 0.04\(^1\). We based our initial sample size of 693 tPA eligible patients on the ability to detect a 0.09 point difference which was the same as between tPA and placebo in NINDS. The endovascular studies found a >0.10 point difference. Based on these pieces of information which were not available when we designed our study, Dr. Grotta reassessed the anticipated difference between groups if the MSU produces a substantial reduction in time to treatment, and felt that a difference of 0.07 is a more realistic goal. Dr. Yamal did not participate in that decision since he is unblinded.

Assuming a 3:2 (1.5) imbalance, 5% LTFU, and using the pooled standard deviation of STEMO & No STEMO group (sd=0.385), numbers of patients needed to detect a difference of 0.07 using a 2-sample t-test is N=1038. Our LTFU so far has been around 5% so we expect this assumption to be reasonable. PCORI has agreed to the increase in sample size and sites.
sufficient to detect a 0.07 difference.

![Figure. Reanalysis of a substantial number of completed stroke trials where conventional mRS outcomes were translated to uw-mRS. Effect sizes reported. From Broderick, et al.](image)

5. ANALYSIS PLAN

5.1. Phase III Trial Analysis

5.1.1. Treatment Group Comparability at Baseline

Although the random enrollment of participants to the two treatment arms and blinded review of tPA eligibility should ensure comparability with respect to known and unknown variables, imbalance may occur by chance. Descriptive statistics for baseline characteristics known or suspected to be associated with outcomes will be prepared for the two treatment groups for all randomized as well as all deemed “eligible for tPA” based on the blinded review. Chi-square statistics and Wilcoxon rank sum tests will be used to evaluate baseline differences between the arms for categorical and continuous variables, respectively. Any variables with baseline differences will be included in secondary adjusted analyses. Also, completers will be compared to non-completers (loss to follow-up for 90 mRS) on these baseline variables to indicate whether missingness may be considered
random.

5.1.2. Primary Clinical Analysis

The mean uw-mRS at 90d along with corresponding two-sided 95% confidence intervals will be compared between groups using a two-sample t-test or Wilcoxon rank sum test if the assumption of normality does not hold. Although the mRS is an ordinal outcome, the difference between the uw-mRS categories has clinical significance and the t-test assumption and central limit theorem are likely satisfied. The analyses of uw-mRS will be adjusted for any baseline uw-mRS, any baseline covariates that are different between the two groups, and covariates associated with mRS, including baseline NIHSS, age, pre-morbid mRS, and previous TIA/stroke, in a linear regression model. Sensitivity analyses of the primary outcome will be conducted including ordinal (shift) analysis using a proportional odds model and proportion achieving a dichotomized outcome of mRS 0-1 vs 2-6 using binary logistic regression.

5.1.3. Sensitivity Analysis of Primary Outcome

We will conduct sensitivity analyses using US-specific utility weights of the 90 day mRS. One method to estimate utility weights uses the EQ5D. EQ5D-5L has been in use for more than a decade. However, the corresponding population-level utility weights for 5L has not been developed for many countries, and most countries only have population-level weights for the much older EQ5D-3L. The latest US weights for EQ5D-3L were developed in 2005. After communication with the EURO-QOL group, with regards to the EQ5D-5L weights, they suggested to use the 5L weights developed by Van Hout et al (2012)\(^7\). Van Hout et al used regression based methods to map the existing 3L weights to 5L weights for all countries that had population-level 3L weights. We will be using those weights unless population-level 5L weights are developed for the US by the time we conduct our final analyses. EURO-QOL informed us that a current study is underway to estimate the population-level 5L utility weights for the US. Finally, we also did a literature review of studies published in the last 2-3 years, which collected EQ5D-5L in the US. All studies used the Van Hout et al weights.

An additional sensitivity analysis will add an indicator of whether the SM subjects that were enrolled during an MSU week affect the treatment effect in a regression model by adding an indicator for these subjects. Also, in a sensitivity analysis, we will move these subjects into the MSU arm to check for consistency of results.

5.1.4. Analyses of Ancillary Clinical Outcomes

We will also compare mRS at 90d (uw-mRS, ∆ uw-mRS from baseline, ordinal (shift) analysis, and proportion achieving 0,1) in tPA treated patients treated within 60 minutes of LSN to patients treated 61-270 minutes, regardless of whether they were on MSU weeks vs. SM weeks. Patients on MSU weeks vs SM weeks will also be compared for differences in (a) the time from LSN to tPA treatment, (b) time from LSN, alarm time, and ED arrival
to start of IAT, and for safety outcomes (i) mortality, (ii) symptomatic intracerebral hemorrhage, and (iii) incidence of tPA treated stroke mimics and transient ischemic attacks.

A logistic regression model will be used to compare 90 day mRS 0-1 vs 2-6 of patients treated with tPA within 60 minutes of symptom onset to similar patients treated 61-270 minutes after onset, adjusting for any imbalances in stroke severity (baseline NIHSS, age, premorbid mRS, and previous stroke/TIA incidence) between the groups at the time of treatment. If baseline characteristics are significantly different between the two non-randomized groups, we will use propensity score analysis to limit potential bias. Also, we expect a higher incidence of spontaneous recovery (TIA) and stroke mimics may occur with earlier observation in the 0-60 minute group compared to those seen 61-270 minutes. The “natural history” of the incidence of spontaneous recovery and stroke mimics will be estimated from patients enrolled into the SM group, and will be considered in analyzing the comparison between patients treated with tPA within 0-60 min vs 61-270 min. Time to treatment and to endovascular procedures will be analyzed using Cox proportional hazards models, similarly to survival. Categorical outcomes will be analyzed using Fisher’s exact test.

Unless there is sufficient power (predetermined before the analysis is begun) the approach to ancillary analysis will generally be the calculation of confidence limits on intervention group differences rather than formal tests of significance as the trial may not have high power to detect difference in all of these outcomes. However, these comparisons will add to the knowledge of the benefits and risks of the intervention.

5.1.5. Subgroup Analysis

Tests of effects within subgroups will be driven by clinical rationale. To reduce the potential for spurious results, we would test for a sub-group treatment interaction at a 0.2 critical level. Any subgroup analyses that are not pre-specified would be considered post hoc and reported as requiring confirmation in future studies. Estimates of the MSU effect will be obtained separately for pre-specified subgroups with significant treatment-by-subgroup interactions, using the methods described above. Pre-specified subgroups include (1) patients treated via TM versus on-site VN, (2) patients treated at various sites, and (3) patients that had the EMS arrive (for SM) or MSU arrive (for MSU) within <1 hr and those that arrived >1hr of LSN. For (3), time will also be considered as a continuous variable and the interaction between time and MSU/SM will be assessed with transformations or restricted cubic splines of time used if appropriate).

When doing the TM subgroup analysis, we anticipate that there may be demographic differences between sites that are doing TM versus onboard VN. For this analysis we will conduct regression models, adjusting for baseline NIHSS, age, pre-morbid mRS, time since last seen normal, and previous TIA/stroke, in a linear regression model.
Analyses of post-randomization sub-groups are subject to many biases. Thus any analyses of post-randomization sub-groups, such as those treated with IAT, would be considered on a case by case basis requiring tailored use of advanced statistical methods and careful interpretation.

5.1.6. Missing Data

We expect no missing data for baseline measures. For 90-day assessments, extensive efforts will be made to ascertain the modified Rankin scores and mortality status, though we anticipate a 10% rate of lost to follow-up. We will perform several approaches for handling missing data. Characteristics of patients who are lost to follow-up will be compared to those that remain in the study to assess the degree of any selection bias, and sensitivity analyses will be performed to evaluate robustness of conclusions to the different missing data approaches. We will use multiple imputation for the final values assuming missing at random, depending on if any significant baseline differences exist between those observations that have a missing value or not. As sensitivity analyses we will report the data with and without imputation. Data will also be stratified according to their missing pattern (e.g., early termination, late termination, and follow-up completers) and variables representing these groups will be used as model covariates in adjusted analyses.

6. MONITORING FOR EFFECTIVENESS AND SAFETY

6.1. Overview

Interim analyses for safety (symptomatic hemorrhage), efficacy/futility (dichotomized mRS 0-1 vs. 2-6), and process (time from alarm until treatment decision) will be conducted when the 90-day mRS has been collected on 50% of the total number of patients that are adjudicated to be tPA-eligible.

6.2. Interim Analyses for Effectiveness

The efficacy interim analysis of the 90 day dichotomized mRS will be a 2-sample, 2-sided test of proportions using a Haybittle-Peto boundary (p=0.001). This will be conducted on the subset that are tPA-eligible based on the blinded adjudication.

6.3. Interim Analyses for Futility

The futility analysis of the 90 day dichotomized mRS (0-1 vs 2-6) will be a 2-sample, 1-sided, test of proportions. The futility analysis will compare patients in MSU weeks vs SM weeks (alpha=0.15). If we reject the null hypothesis that the percentage of favorable outcomes (mRS<2) in patients in the MSU weeks is greater than or equal to the percentage of favorable outcomes in patients in the SM weeks plus 10%, we conclude that completing the trial would likely be futile. The futility hypotheses are: $H_0: p_{MSU} - p_{SM} \geq \Delta$ versus $H_A: p_{MSU} - p_{SM} < \Delta$.
where $p_{MSU}$ and $p_{SM}$ are the proportions of participants expected to have a favorable mRS outcome in the MSU and SM groups, respectively, and $\Delta$ denotes the 10% increase in favorable outcomes over SM considered clinically meaningful. This will be conducted on the subset that are tPA-eligible based on the blinded adjudication.

6.4. Safety Analyses

Rates of symptomatic hemorrhage will be compared using a Fisher’s exact test (alpha=0.05). This will be conducted on all enrolled tPA-treated patients, excluding any that had an ICH on their baseline CT scan.

6.5. Process Analysis

Time from alarm to treatment decision will be compared using a one-sided Wilcoxon rank sum test (alpha=0.05) to test if the time is longer for the MSU arm. This will be conducted on the subset that are tPA-eligible based on the blinded adjudication. MSU-by-site interaction terms will be included in a regression model to test if these differ by site and if the interactions are significant then within-site tests will be conducted.

7. REPORTING PROCEDURES

7.1. CONSORT Diagram

We will account for every subject randomized into the study using a CONSORT diagram.

7.2. Primary Reporting for the BEST-MSU Study

We will account for every subject randomized into the study using a CONSORT diagram. Primary reporting for the BEST-MSU study will follow the classic CONSORT Checklist items (see appendix).

7.3. SMC Reports

Standard format for SMC reports will be developed and sent to the SMC for review before the initial safety analyses are presented, and the format will be added as an appendix to this report.

7.4. Publications

Before the BEST-MSU CCC begins an analysis for a manuscript or presentation, the first author or writing group will have their hypotheses and analysis plan reviewed and approved by a designated team at the BEST-MSU DCC.
8. REFERENCES


# Appendix A: CONSORT Checklist

## CONSORT CHECKLIST

<table>
<thead>
<tr>
<th>Section and Topic</th>
<th>Item No.</th>
<th>Checklist Item</th>
<th>Reported on Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title and abstract</td>
<td>1a</td>
<td>Identification as a randomized trial in the title</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1b</td>
<td>Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>2a</td>
<td>Scientific background and explanation of rationale</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>Specific objectives or hypotheses</td>
<td></td>
</tr>
<tr>
<td>Methods</td>
<td>3a</td>
<td>Description of trial design (such as parallel, factorial) including allocation ratio</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>4a</td>
<td>Eligibility criteria for participants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4b</td>
<td>Settings and locations where the data were collected</td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td>5</td>
<td>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>6a</td>
<td>Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6b</td>
<td>Any changes to trial outcomes after the trial commenced, with reasons</td>
<td></td>
</tr>
<tr>
<td>Sample size</td>
<td>7a</td>
<td>How sample size was determined</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7b</td>
<td>When applicable, explanation of any interim analyses and stopping guidelines</td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>8a</td>
<td>Method used to generate the random allocation sequence</td>
<td></td>
</tr>
<tr>
<td>Sequence generation</td>
<td>8b</td>
<td>Type of randomization; details of any restriction (such as blocking and block size)</td>
<td></td>
</tr>
<tr>
<td>Allocation concealment mechanism</td>
<td>9</td>
<td>Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned</td>
<td></td>
</tr>
<tr>
<td>Implementation</td>
<td>10</td>
<td>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</td>
<td></td>
</tr>
<tr>
<td>Blinding</td>
<td>11a</td>
<td>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11b</td>
<td>If relevant, description of the similarity of interventions</td>
<td></td>
</tr>
<tr>
<td>Statistical methods</td>
<td>12a</td>
<td>Statistical methods used to compare groups for primary and secondary outcomes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12b</td>
<td>Methods for additional analyses, such as subgroup analyses and adjusted analyses</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>13a</td>
<td>For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome</td>
<td></td>
</tr>
<tr>
<td>Participant flow (a diagram is strongly recommended)</td>
<td>13b</td>
<td>For each group, losses and exclusions after randomization, together with reasons</td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>14a</td>
<td>Dates defining the periods of recruitment and follow-up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14b</td>
<td>Why the trial ended or was stopped</td>
<td></td>
</tr>
<tr>
<td>Baseline data</td>
<td>15</td>
<td>A table showing baseline demographic and clinical characteristics for each group</td>
<td></td>
</tr>
<tr>
<td>Numbers analyzed</td>
<td>16</td>
<td>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</td>
<td></td>
</tr>
<tr>
<td>Outcomes and estimation</td>
<td>17a</td>
<td>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17b</td>
<td>For binary outcomes, presentation of both absolute and relative effect sizes is recommended</td>
<td></td>
</tr>
<tr>
<td>Ancillary analyses</td>
<td>18</td>
<td>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory</td>
<td></td>
</tr>
<tr>
<td>Harms</td>
<td>19</td>
<td>All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)</td>
<td></td>
</tr>
<tr>
<td>Comment</td>
<td>20</td>
<td>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</td>
<td></td>
</tr>
<tr>
<td>Limitations</td>
<td>21</td>
<td>Generalizability (external validity, applicability) of the trial findings</td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td>22</td>
<td>Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence</td>
<td></td>
</tr>
<tr>
<td>Other information</td>
<td>23</td>
<td>Registration number and name of trial registry</td>
<td></td>
</tr>
<tr>
<td>Protocol</td>
<td>24</td>
<td>Where the full trial protocol can be accessed, if available</td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>25</td>
<td>Sources of funding and other support (such as supply of drugs), role of funders</td>
<td></td>
</tr>
</tbody>
</table>

©2010 American Medical Association. All rights reserved.